Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
Thomas M. Cardillo(Immunomedics (United States)), David M. Goldenberg(Immunomedics (United States))
Cited by 50
Related Papers
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
|Oncotarget|2015|464
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
|Oncotarget|2018|306
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
|BMC Cancer|2007|273
Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement
|British Journal of Cancer|2010|52